Literature DB >> 7944532

Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major.

R G Grundy1, K A Woods, M O Savage, J P Evans.   

Abstract

Disturbances of growth and development in patients with thalassaemia receiving hypertransfusion programmes are well recognised and are most likely to be due to iron overload. The extent of endocrine dysfunction was investigated in a group of 18 patients thought to have been treated by acceptable modern standards, 11 of whom could be considered as well chelated. Assessment of growth and puberty showed a wide variation in height SD scores with five patients having significantly short stature. Most patients are progressing through puberty normally with the exception of two boys with marked pubertal delay. The most prominent finding was that growth hormone responses to glucagon stimulation were significantly impaired in all of the patients with iron overload. Basal endocrine assessment showed primary hypothyroidism in two patients aged 16.8 and 12.9 years with plasma thyroxine-concentrations of 86 and 59 nmol/l (normal range 65-165 nmol/l) and plasma thyroid stimulating hormone 10.2 and 30.3 mU/l (normal range 0.5-5 mU/l). One patient had diabetes mellitus. These results show that even when ideal management is sought a significant amount of endocrine damage occurs; surveillance of these patients is thus essential.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944532      PMCID: PMC1029942          DOI: 10.1136/adc.71.2.128

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Compliance with therapy in Cooley's anaemia.

Authors:  C Vullo; A Di Palma
Journal:  Prog Clin Biol Res       Date:  1989

2.  Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major.

Authors:  C Pintor; S G Cella; P Manso; R Corda; C Dessĭ; V Locatelli; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

3.  Insulin dependent diabetes in thalassaemia.

Authors:  V De Sanctis; M G Zurlo; E Senesi; C Boffa; L Cavallo; F Di Gregorio
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

4.  Survival and desferrioxamine in thalassaemia major.

Authors:  B Modell; E A Letsky; D M Flynn; R Peto; D J Weatherall
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-10

5.  Primary hypothyroidism and the low T3 syndrome in thalassaemia major.

Authors:  A R Sabato; V de Sanctis; G Atti; L Capra; B Bagni; C Vullo
Journal:  Arch Dis Child       Date:  1983-02       Impact factor: 3.791

6.  Early iron overload in beta-thalassaemia major: when to start chelation therapy?

Authors:  S Fargion; M T Taddei; V Gabutti; A Piga; A Di Palma; L Capra; G Fontanelli; A Avanzini
Journal:  Arch Dis Child       Date:  1982-12       Impact factor: 3.791

7.  Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect.

Authors:  J Leger; R Girot; H Crosnier; M C Postel-Vinay; R Rappaport
Journal:  J Clin Endocrinol Metab       Date:  1989-08       Impact factor: 5.958

8.  Endocrine functioning in multitransfused prepubertal patients with homozygous beta-thalassemia.

Authors:  A Masala; T Meloni; D Gallisai; S Alagna; P P Rovasio; S Rassu; A F Milia
Journal:  J Clin Endocrinol Metab       Date:  1984-04       Impact factor: 5.958

9.  Depressed serum somatomedin activity in beta-thalassemia.

Authors:  P Saenger; E Schwartz; A L Markenson; J H Graziano; L S Levine; M I New; M W Hilgartner
Journal:  J Pediatr       Date:  1980-02       Impact factor: 4.406

10.  No evidence for a defect in growth hormone binding to liver membranes in thalassemia major.

Authors:  M C Postel-Vinay; R Girot; J Leger; J F Hocquette; P McKelvie; A Amar-Costesec; R Rappaport
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

View more
  10 in total

1.  Thyroid function in major thalassemia patients: Is it related to height and chelation therapy?

Authors:  Peiman Eshragi; Ahmad Tamaddoni; Khadijeh Zarifi; Amir Mohammadhasani; Majid Aminzadeh
Journal:  Caspian J Intern Med       Date:  2011

Review 2.  Growth of children with beta-thalassemia major.

Authors:  Louis Ck Low
Journal:  Indian J Pediatr       Date:  2005-02       Impact factor: 1.967

3.  Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.

Authors:  Enas A Hamed; Nagla T ElMelegy
Journal:  Ital J Pediatr       Date:  2010-05-25       Impact factor: 2.638

4.  Frequency of glomerular dysfunction in children with Beta thalassaemia major.

Authors:  Basma A Ali; Ahmed M Mahmoud
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

5.  Screening of growth hormone deficiency in short thalassaemic patients and effect of L-carnitine treatment.

Authors:  Amal El Beshlawy; Soha M Abd El Dayem; Fatma El Mougy; Esmat Abd El Gafar; Hend Samir
Journal:  Arch Med Sci       Date:  2010-03-09       Impact factor: 3.318

6.  Hypothyroidism in β-Thalassemia Intermedia Patients with and without Hydroxyurea.

Authors:  Omid Reza Zekavat; Ali Reza Makarem; Sezaneh Haghpanah; Zohreh Karamizadeh; Parvin Javad; Mehran Karimi
Journal:  Iran J Med Sci       Date:  2014-01

7.  Comparing different markers of tubular dysfunction in transfusion-dependent thalassemia patients.

Authors:  Ilham Youssry; Samuel Makar; Khalil Abdelkhalek; Dina Hisham; Happy Sawires
Journal:  Int Urol Nephrol       Date:  2021-06-24       Impact factor: 2.370

8.  Thyroid function status and echocardiographic abnormalities in patients with Beta thalassemia major in bahrain.

Authors:  Taysir S Garadah; Najat A Mahdi; Ahmed M Jaradat; Zuheir A Hasan; Das S Nagalla
Journal:  Clin Med Insights Cardiol       Date:  2013-01-28

9.  Glucose homeostasis in Egyptian children and adolescents with β-Thalassemia major: Relationship to oxidative stress.

Authors:  Kotb Abbass Metwalley; Abdel-Rahman Abdel-Hamed El-Saied
Journal:  Indian J Endocrinol Metab       Date:  2014-05

Review 10.  Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives.

Authors:  Karim Bayanzay; Lama Alzoebie
Journal:  J Blood Med       Date:  2016-08-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.